Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs using PBBM Modeling: Industry Case Studies

Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs using PBBM Modeling: Industry Case Studies

Authors: Mitra A, Zhu W, Parrott N
Software: GastroPlus®
Division: PBPK

Acid-reducing agents (ARA) such as antacids, histamine H2-receptor antagonists, and proton pump inhibitors are widely prescribed in several disease states.

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling

Authors: Chen Y, Ke M, Xu J, Lin C
Publication: AAPS PharmSciTech
Software: GastroPlus®

Oseltamivir is a neuraminidase inhibitor widely used to treat and prevent influenza A and B infections, although its safety and pharmacokinetics have not been evaluated in patients with severe hepatic impairment.

In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385

In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385

Software: GastroPlus®

Parkinson's disease is one of the most common neurodegenerative diseases. Adenosine regulates the response to other neurotransmitters in the brain regions related to motor function.

User guide for the discovery of potential drugs via protein structure prediction and ligand docking simulation

User guide for the discovery of potential drugs via protein structure prediction and ligand docking simulation

Publication: Journal of Microbiology
Software: ADMET Predictor®

Due to accumulating protein structure information and advances in computational methodologies, it has now become possible...

The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias

The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias

Authors: Roskoski Jr R
Publication: Pharmacological Research
Software: ADMET Predictor®

Flt3 is expressed by early myeloid and lymphoid progenitor cells and it regulates the proliferation and differentiation of hematopoietic cells.

Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice

Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice

Publication: AAPS J

The orally available novel small molecule SHetA2 is the lead sulfur-containing heteroarotinoid that selectively inhibits cancer cells over normal cells, and is currently under clinical development for...

New insights into the vancomycin‐induced nephrotoxicity using in vitro metabolomics combined with physiologically based pharmacokinetic modeling

New insights into the vancomycin‐induced nephrotoxicity using in vitro metabolomics combined with physiologically based pharmacokinetic modeling

Publication: J Appl Toxicol
Software: GastroPlus®

Vancomycin is a first‐line treatment for invasive infections caused by multidrug‐resistant gram‐positive bacteria.